NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKI

被引：6
作者：
Facchinetti, Francesco [1 ]
Tiseo, Marcello [1 ]
Gnetti, Letizia [2 ]
Silini, Enrico Maria [2 ]
Ardizzoni, Andrea [1 ]
机构：
[1] Univ Hosp Parma, Med Oncol Unit, I-43100 Parma, Italy
[2] Univ Hosp Parma, Surg Pathol Unit, I-43100 Parma, Italy
来源：
LUNG CANCER | 2013年 / 82卷 / 01期
关键词：
CARCINOMA;
D O I：
10.1016/j.lungcan.2013.07.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：177 / 178
页数：2
相关论文
共 39 条
  • [31] Infection with human cytomegalovirus, Epstein-Barr virus, and high-risk types 16 and 18 of human papillomavirus in EGFR-mutated lung adenocarcinoma
    Harabajsa, Suzana
    Sdfcic, Hajdi
    Klasic, Marija
    Milavic, Marija
    Lepej, Snjezana Zidovec
    Grgic, Ivana
    Petranovic, Matea Zajc
    Jakopovic, Marko
    Smojver-Jezek, Silvana
    Korac, Petra
    CROATIAN MEDICAL JOURNAL, 2023, 64 (02) : 84 - 92
  • [32] Narrative review of stereotactic body radiation therapy combined with tyrosine kinase inhibitors for oligometastatic EGFR-mutated non-small cell lung cancer: present and future developments
    Zhao, Xinchen
    Zhang, Shengwei
    Sun, Xiaoyue
    Lin, Yao
    Capone, Luca
    Ko, Eric C.
    Kann, Benjamin H.
    Li, Yi
    Wang, Xiaoshan
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (06) : 1383 - 1395
  • [33] Enhanced anticancer effect of cetuximab combined with stabilized silver ion solution in EGFR-positive lung cancer cells
    Ozkan, Aysun
    Erdogan, Ayse
    Ozkan, Odul
    Manguoglu, Esra
    Kiraz, Nadir
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2019, 44 (04): : 426 - 437
  • [34] Use of Cabozantinib in a Patient With EGFR-Mutated Non-Small-Cell Lung Cancer Harboring Acquired CCDC6-RET Fusion
    Chae, Young Kwang
    Viveiros, Pedro
    Heleno, Caio T.
    Bilal, Haris
    Sukhadia, Bhoomika A.
    Oh, Michael S.
    Sheikh, Muhamad Mubbashir
    Iams, Wade T.
    Park, Lee Chun
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 5
  • [35] The Correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) Classification With Prognosis and EGFR Mutation in Lung Adenocarcinoma
    Yanagawa, Naoki
    Shiono, Satoshi
    Abiko, Masami
    Ogata, Shin-ya
    Sato, Toru
    Tamura, Gen
    ANNALS OF THORACIC SURGERY, 2014, 98 (02) : 453 - 458
  • [36] The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
    Greve, Gabriele
    Schiffmann, Insa
    Pfeifer, Dietmar
    Pantic, Milena
    Schueler, Julia
    Luebbert, Michael
    BMC CANCER, 2015, 15
  • [37] In vitro antiproliferative effect of trastuzumab (Herceptin®) combined with cetuximab (Erbitux®) in a model of human non-small cell lung cancer expressing EGFR and HER2
    Privitera, G.
    Luca, T.
    Musso, N.
    Vancheri, C.
    Crimi, N.
    Barresi, V.
    Condorelli, D.
    Castorina, S.
    CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 16 (02) : 161 - 168
  • [38] Brain Metastasis from EGFR-Mutated Non-Small Cell Lung Cancer: Secretion of IL11 from Astrocytes Up-Regulates PDL1 and Promotes Immune Escape
    Tang, Mengyi
    Xu, Mingxin
    Wang, Jian
    Liu, Ye
    Liang, Kun
    Jin, Yinuo
    Duan, Wenzhe
    Xia, Shengkai
    Li, Guohui
    Chu, Huiying
    Liu, Wenwen
    Wang, Qi
    ADVANCED SCIENCE, 2024, 11 (26)
  • [39] Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials
    Gao, Guanghui
    Ren, Shengxiang
    Li, Aiwu
    Xu, Jianfang
    Xu, Qinghua
    Su, Chunxia
    Guo, Jian
    Deng, Qinfang
    Zhou, Caicun
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (05) : E822 - E829
1234